Home Cart Sign in  
Chemical Structure| 62596-29-6 Chemical Structure| 62596-29-6

Structure of Morusin
CAS No.: 62596-29-6

Chemical Structure| 62596-29-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Morusin shows suppression of NFκB and STAT3 in many cancer cell lines including HT-29, A549, MCF-7, and MDA-MB-231. It is a flavonoid purified from the root bark of morus alba L. with antitumor activity.

Synonyms: Mulberrochromene; NSC 649220

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Morusin

CAS No. :62596-29-6
Formula : C25H24O6
M.W : 420.45
SMILES Code : O=C1C2=C(O)C=C3C(C=CC(C)(C)O3)=C2OC(C4=CC=C(O)C=C4O)=C1C/C=C(C)\C
Synonyms :
Mulberrochromene; NSC 649220
MDL No. :MFCD09953814
InChI Key :XFFOMNJIDRDDLQ-UHFFFAOYSA-N
Pubchem ID :5281671

Safety of Morusin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Morusin

JAK-STAT
pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human breast cancer cells (MDA-MB-231) 1, 2, 4, 6, 8 μg/ml 1, 2, 3, 4, 5 days Test the cytotoxicity of Morusin on MDA-MB-231 cells, IC50 was 3.86 μg/ml J Exp Clin Cancer Res. 2015 Nov 4;34:137.
Human breast cancer cells (MCF-7) 1, 2, 4, 6, 8 μg/ml 1, 2, 3, 4, 5 days Test the cytotoxicity of Morusin on MCF-7 cells, IC50 was 2.71 μg/ml J Exp Clin Cancer Res. 2015 Nov 4;34:137.
Murine breast cancer cells (EMT6) 1, 2, 4, 6, 8 μg/ml 1, 2, 3, 4, 5 days Test the cytotoxicity of Morusin on EMT6 cells, IC50 was 1.87 μg/ml J Exp Clin Cancer Res. 2015 Nov 4;34:137.
Murine breast cancer cells (4T1) 1, 2, 4, 6, 8 μg/ml 1, 2, 3, 4, 5 days Test the cytotoxicity of Morusin on 4T1 cells, IC50 was 2.03 μg/ml J Exp Clin Cancer Res. 2015 Nov 4;34:137.
Human normal mammary epithelial cells (MCF-10A) 1, 2, 4, 6, 8 μg/ml 1, 2, 3, 4, 5 days Test the cytotoxicity of Morusin on normal mammary epithelial cells, IC50 was 9.48 μg/ml J Exp Clin Cancer Res. 2015 Nov 4;34:137.
Aortic valve interstitial cells (VICs) 1 μM 21 days To evaluate the long-term effect of Morusin on osteogenic differentiation of VICs. Results showed Morusin significantly reduced calcific nodule formation. Adv Sci (Weinh). 2024 May;11(20):e2307319.
Aortic valve interstitial cells (VICs) 1 μM 7 days To evaluate the inhibitory effect of Morusin on osteogenic differentiation of VICs. Results showed Morusin significantly suppressed OM-induced ALP activity and calcific nodule formation. Adv Sci (Weinh). 2024 May;11(20):e2307319.
Bone marrow mesenchymal stem cells (BMSCs) 2.5-10 μM 3, 5, 7, 14 days Promoted proliferation and osteogenic differentiation of BMSCs, with 10 μM Morusin showing the strongest effect Stem Cell Res Ther. 2021 Mar 12;12(1):173.
FH c cells (normal fetal colonic mucosa cells) 9.1, 18.2, 36.4 µM 24, 48, 72 hours Morusin did not significantly affect the proliferation of normal colonic mucosa cells FH c. Int J Mol Med. 2021 Apr;47(4):1.
HCT116 human colorectal cancer cells 9.1, 18.2, 36.4 µM 24, 48, 72 hours Morusin significantly inhibited the proliferation of HCT116 sphere cells in a concentration- and time-dependent manner. Int J Mol Med. 2021 Apr;47(4):1.
SW480 cells 0, 2.5, 5 μM 24 hours Evaluate the effect of Morusin on SW480 cell colony formation, results showed Morusin reduced the number of colonies Cells. 2021 Aug 12;10(8):2065.
HCT116 cells 0, 2.5, 5 μM 24 hours Evaluate the effect of Morusin on HCT116 cell colony formation, results showed Morusin reduced the number of colonies Cells. 2021 Aug 12;10(8):2065.
SW480 cells 0, 2.5, 5, 10 μM 24 hours Evaluate the effect of Morusin on SW480 cell viability, results showed Morusin inhibited cell viability Cells. 2021 Aug 12;10(8):2065.
HCT116 cells 0, 2.5, 5, 10 μM 24 hours Evaluate the effect of Morusin on HCT116 cell viability, results showed Morusin inhibited cell viability Cells. 2021 Aug 12;10(8):2065.
HeLa cells 1-10 μM 12 hours Inhibited phosphorylation of p70S6K1, promoted autophagy, and slowed cell senescence elegans via suppressing nutrient-sensing pathways. Geroscience.
RAW264.7 macrophages 9.87 ± 0.59 μM 24 hours Evaluate the inhibitory effect of Morusin on NO production in RAW264.7 macrophages, showing that Morusin exhibited stronger anti-NO activity than the positive control quercetin. Antioxidants (Basel). 2022 Nov 11;11(11):2222.
Ruminal epithelial cells (RECs) 25 µg/mL and 50 µg/mL 12 hours Morusin exerted anti-inflammatory effects in a concentration-dependent manner, with 50 µg/mL Morusin significantly downregulating the gene expression of TNF-α, CD40, IL-6, and CCL20 in RECs Int J Mol Sci. 2022 Nov 20;23(22):14428.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Caenorhabditis elegans Wild-type N2 and akt-1(ok525) and akt-2(ok393) mutants NGM media or E. coli OP50-1 feeding 120 μM Starting from the L4 stage and continued throughout lifespan Extended mean lifespan, increased reproduction, without affecting health metrics (e.g., pharyngeal pumping rate) elegans via suppressing nutrient-sensing pathways. Geroscience.
Nude mice Subcutaneous xenograft model of human breast cancer MCF-7 cells Intraperitoneal injection 5, 10 mg/kg Three times weekly for 4 weeks Test the tumor inhibitory effect of Morusin on MCF-7 xenografts, tumor inhibitory rates were 46.5% and 64.1% at doses of 5 mg/kg and 10 mg/kg, respectively J Exp Clin Cancer Res. 2015 Nov 4;34:137.
ApoE−/− mice High-fat Western diet-induced aortic valve calcification model Gavage 40 mg/kg Twice a week for 24 weeks To evaluate the therapeutic effect of Morusin on aortic valve calcification. Results showed Morusin significantly alleviated high-fat diet-induced aortic valve calcification and reduced ROS levels. Adv Sci (Weinh). 2024 May;11(20):e2307319.
Wistar rats Ovariectomy-induced osteoporosis model Intragastric administration 40 mg/kg Every 5 days for 4 weeks Morusin attenuated bone loss in OVX rats, increased trabecular number and bone mass indexes Stem Cell Res Ther. 2021 Mar 12;12(1):173.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.38mL

0.48mL

0.24mL

11.89mL

2.38mL

1.19mL

23.78mL

4.76mL

2.38mL

References

 

Historical Records

Categories